Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

BACKGROUND: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has shown remarkable results in malignant melanoma (MM), while studies on the potential in other cancer diagnoses are sparse. Further, the prospect of using checkpoint inhibitors (CPIs) to support TIL production and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kverneland, Anders Handrup, Chamberlain, Christopher Aled, Borch, Troels Holz, Nielsen, Morten, Mørk, Sofie Kirial, Kjeldsen, Julie Westerlin, Lorentzen, Cathrine Lund, Jørgensen, Lise Pyndt, Riis, Lene Buhl, Yde, Christina Westmose, Met, Özcan, Donia, Marco, Marie Svane, Inge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491427/
https://www.ncbi.nlm.nih.gov/pubmed/34607899
http://dx.doi.org/10.1136/jitc-2021-003499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491427/
https://www.ncbi.nlm.nih.gov/pubmed/34607899
http://dx.doi.org/10.1136/jitc-2021-003499

Ejemplares similares